FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
HILLMAN JEFFREY D
   2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ORNI] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer
(Last)
(First)
(Middle)
13700 PROGRESS BLVD		 3. Date of Earliest Transaction (Month/Day/Year)
12/01/2009
(Street)

ALACHUA, FL 32615		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $ 0.27 12/01/2009   A   700,000     (1) 12/01/2019 Common Stock 700,000 $ 0 700,000 D  
Employee Stock Option (Right to Buy) $ 0.27 12/01/2009   A   100,000     (2)(3)   (3) Common Stock 100,000 $ 0 100,000 D (2)  
Employee Stock Option (Right to Buy) $ 0.27 12/01/2009   A   125,000     (2)(4)   (4) Common Stock 125,000 $ 0 125,000 D (2)  
Employee Stock Option (Right to Buy) $ 0.27 12/01/2009   A   100,000     (2)(5)   (5) Common Stock 100,000 $ 0 100,000 D (2)  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
HILLMAN JEFFREY D
13700 PROGRESS BLVD
ALACHUA, FL 32615		   X     Chief Scientific Officer  

Signatures

 /s/ Mark A. Catchur, as attorney-in-fact for Jeffrey D. Hillman   12/03/2009
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Such stock option may be exercised as follows: one-third on the first anniversary of the date of grant (12/01/2010), with an additional one-third becoming exercisable on each of the following two anniversaries of the date of grant. Notwithstanding such time vesting, the options shall become immediately vested in full in the event of a change in control of the Company as specified in the stock option agreement between Dr. Hillman and the Company.
(2) The options are included herein, notwithstanding that the exercisability of such option awards is subject to the achievement of certain Company performance targets.
(3) The options with respect to up to 100,000 shares of common stock shall become vested and exercisable by Dr. Hillman upon the first calendar quarter in which the Company reports a Net Profit in a Form 10-Q Report or Form 10-K Report, as the case may be, that is publicly filed with the Securities and Exchange Commission ("SEC") under the Securities Exchange Act of 1934 as amended (the "Exchange Act"). These options expire and are void unless exercised on or before the earlier to occur of (i) December 1, 2019, or (ii) the time in which the Company ceases being obligated to file quarterly and annual reports with the SEC under the Exchange Act.
(4) The options with respect to up to 125,000 shares of common stock shall become vested and exercisable by Dr. Hillman in tranches, on the last day of any three consecutive month period upon either (i) the shipment or invoicing of of a certain designated amount of units or boxes of consumer products during each of three consecutive months, or (ii) the shipment or invoicing of a designated amount of units or boxes of consumer products during any three consecutive month period. These options expire and are void unless they become vested and exercisable as follows: one-third on September 1, 2010, one-third on December 1, 2010, and one-third on March 1, 2010. To the extent any options become vested and exercisable (that have not expired in accordance with expiration schedule), they shall expire and are void unless exercised on or before December 1, 2019.
(5) The options with respect to up to 100,000 shares of common stock shall become vested and exercisable by Dr. Hillman upon the occurrence of certain designated milestones related to scientific development of the Company technology's. The options expire and are void unless they become vested and exercisable on or before December 31, 2011. To the extent any of these options become vested and exercisable, they shall expire and be void unless exercised on or before December 1, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.